S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:CRTX

Cortexyme (CRTX) Stock Forecast, Price & News

$1.53
+0.07 (+4.79%)
(As of 05/30/2023 ET)
Compare
Today's Range
$1.43
$1.55
50-Day Range
$1.37
$1.79
52-Week Range
$1.78
$40.66
Volume
101,745 shs
Average Volume
620,672 shs
Market Capitalization
$46.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CRTX stock logo

About Cortexyme (NASDAQ:CRTX) Stock

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Stock News Headlines

Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
See More Headlines
Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Company Calendar

Last Earnings
8/09/2021
Today
6/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:CRTX
CUSIP
21924P10
Fax
N/A
Employees
55
Year Founded
2012

Profitability

Net Income
$-89,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
21,739,000
Market Cap
$46.13 million
Optionable
Not Optionable
Beta
1.40

Social Links


Key Executives

  • Dr. Leslie J. Holsinger Ph.D. (Age 57)
    Exec. VP of R&D
    Comp: $603.85k
  • Dr. Dirk Thye M.D. (Age 52)
    CEO & Director
  • Mr. Ted Monohon (Age 56)
    VP of Fin., Principal Financial Officer & Chief Accounting Officer
  • Mr. Brendan Hannah M.B.A.
    Chief Bus. Officer
  • Dr. Karen L. Smith L.L.M (Age 54)
    L.L.M., M.B.A., M.D., PH.D., Chief Medical Officer













CRTX Stock - Frequently Asked Questions

How have CRTX shares performed in 2023?

Cortexyme's stock was trading at $0.6374 at the start of the year. Since then, CRTX stock has increased by 140.0% and is now trading at $1.53.
View the best growth stocks for 2023 here
.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings data on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.05.

What other stocks do shareholders of Cortexyme own?
When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Caryn Gordon Mcdowell, Casey Lynch, Christopher P Lowe, David Lamond, Epiq Capital Group, Llc, Leslie Holsinger, Margaret Mcloughlin, Michael J Detke and Stephen S Dominy.
View institutional ownership trends
.

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $1.53.

How much money does Cortexyme make?

Cortexyme (NASDAQ:CRTX) has a market capitalization of $46.13 million. The biopharmaceutical company earns $-89,940,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cortexyme.com. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at ir@cortexyme.com.

This page (NASDAQ:CRTX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -